杉泽生物：红杉中国宣布完成对莫西沙星全球业务收购，原辉瑞高管金肖东出任CEO

Core Insights - Sequoia China has completed the global acquisition of the core product moxifloxacin (brand name: Avelox®) related to fluoroquinolone antibiotics on February 2, 2026, establishing Hangzhou Shanze Biological Pharmaceutical Co., Ltd. [1] - Shanze Biological and its parent company Ascenda Pte. Ltd. have acquired specific assets for Avelox® globally, including drug registration certificates, intellectual property, and business contracts, ensuring a solid foundation for the product's ongoing supply and future development [1] - Jin Xiaodong has recently been appointed as the CEO of Shanze Biological, bringing decades of experience in the pharmaceutical industry, previously serving as General Manager at Pfizer China [1]